Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Axl receptor tyrosine kinase is implicated in cancer growth, metastasis, and poor prognosis, particularly in lung cancers.
• The precise molecular mechanisms of Axl-driven cancer progression, involving pathways like MAPK and EMT, remain incompletely understood.
• Identifying molecules regulated by Axl kinase is crucial for understanding its role in lung adenocarcinoma.

Discussion:

• AXL expression correlates with immune checkpoint molecules and chemokine receptors in non-small-cell lung cancers.
• AXL significantly correlates with programmed death-ligand 1 (PD-L1) and CXC chemokine receptor 6 (CXCR6) in lung adenocarcinoma, especially in EGFR-mutation-positive cases.
• Pharmacological inhibition of Axl kinase reduces PD-L1 and CXCR6 mRNA levels in EGFR-mutation-positive lung cancer cell lines.

Key Insights:

• Axl kinase acts as a novel driver of immune checkpoint molecules and chemokine signaling pathways in lung adenocarcinoma progression.
• AXL upregulation is linked to key mediators of immune evasion and tumor microenvironment modulation.
• The study identifies a specific molecular link between AXL and PD-L1/CXCR6 in a subset of lung adenocarcinomas.

Outlook:

• Axl kinase inhibition presents a potential therapeutic avenue for lung adenocarcinomas with high AXL expression.
• Further clinical trials are warranted to evaluate the efficacy of Axl kinase inhibitors in this patient subset.
• Targeting AXL may synergize with existing immunotherapies by modulating the tumor immune microenvironment.